Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C

Journal of Medical Virology

Volumn 89, Issue 4, 2017, Pages 660-664

  Marciano, Sebastián ^a   Haddad, Leila ^a   Plazzotta, Fernando ^a   Mauro, Ezequiel ^a   Terraza, Sergio ^a   Arora, Sanjeev ^b   Thornton, Karla ^b   Ríos, Beatriz ^c   García Dans, Carlos ^d   Ratusnu, Natalia ^e   Calanni, Liliana ^f   Allevato, José ^g   Sirotinsky, María Ester ^h   Pedrosa, Marcos ⁱ   Gadano, Adrián ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c Centro de Investigación CEIN   (Argentina)

^d Hospital Zonal Ramón Carrillo   (Argentina)

^e Hospital Regional Ushuaia Gobernador Ernesto Campos   (Argentina)

^f Hospital Provincial de Neuquén E Castro Rendón   (Argentina)

^g Instituto Norpatagónico de Gastroenetrología y Endoscopía Digestiva de Neuquén   (Argentina)

^h Centro de Estudios Digestivos (CEDIG)   (Argentina)

ⁱ ABBVIE INC   (United States)

Author keywords

anti hepatitis C virus DAA (directly acting; antiviral agents; antivirals); biostatistics bioinformatics; education; social networks; social science

Indexed keywords

ARGENTINA; ARTICLE; EVALUATION STUDY; FIBROSIS; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEPATITIS C; HEPATOLOGIST; HUMAN; INFECTIOUS DISEASE SPECIALIST; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICIAN; PROFESSIONAL COMPETENCE; TELEMONITORING; ADULT; ANIMAL; DISEASE MANAGEMENT; EPIDEMIOLOGY; FEMALE; HEALTH SERVICES RESEARCH; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; PROCEDURES; QUESTIONNAIRE; TELEMEDICINE;

ADULT; ANIMALS; ARGENTINA; CONTROLLED BEFORE-AFTER STUDIES; DISEASE MANAGEMENT; EDUCATION, MEDICAL; FEMALE; HEALTH SERVICES RESEARCH; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHYSICIANS; SURVEYS AND QUESTIONNAIRES; TELEMEDICINE;

EID: 84992176726     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24668     Document Type: Article

References (13)

1. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, Parish B, Brown J, Komaromy M, Colleran K, Bankhurst A, Katzman J, Harkins M, Curet L, Cosgrove E, Pak W. 2010. Expanding access to hepatitis C virus treatment-extension for community healthcare outcomes (ECHO) project: Disruptive innovation in specialty care. Hepatology 52:1124–1133.
2. Arora S, Thornton K, Komaromy M, Kalishman S, Katzman J, Duhigg D. 2014. Demonopolizing medical knowledge. Acad Med 89:30–32.
3. Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. 2016. Chronic hepatitis C: This and the new era of treatment. World J Hepatol 8:92–106.
4. Cejas NG, Villamil FG, Lendoire JC, Tagliafichi V, Lopez A, Krogh DH, Soratti CA, Bisigniano L. 2013. Improved waiting-list outcomes in Argentina after the adoption of a model for end-Stage liver disease-Based liver allocation policy. Liver Transpl 19:711–720.
5. Chen T, Terrault N. 2016. Treatment of chronic hepatitis C in patients with cirrhosis. Curr Opin Gastroenterol 32:143–151.
6. Gaite LA, Marciano S, Galdame OA, Gadano AC. 2014. Hepatitis C in Argentina: Epidemiology and treatment. Hepat Med 6:35–43.
7. Hanafiah Mohd, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: New estimates of age-Specific antibody to HCV seroprevalence. Hepatology 57:1333–1342.
8. Majumdar A, Kitson MT. 2016. S. K. systematic review: Current concepts and challenges for the direct-Acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 43:1276–1292.
9. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. 2015. Drug–drug interaction profile of the all-oral anti-Hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 63:20–29.
10. Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, El Ali, Din Z. 2015. Hepatitis C virus: A global view. World J Hepatol 7:2676–2680.
11. Pawlotsky J-M. 2014. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 146:1176–1192.
12. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–538.
13. Zopf S, Kremer AE, Neurath MF, Siebler J. 2016. Advances in hepatitis C therapy: What is the current State—What come's next? World J Hepatol 8:139–147.